Optimized CDK19 PET Tracers: Spirocyclic-Driven Design and Prostate Cancer Imaging
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.5c01389 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Jiang Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin …. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Cyclin-Dependent Kinases, Positron-Emission Tomography, Drug Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Medical Sciences, Tianjin Medical University.
Abstract (Originalsprache)
Cyclin-dependent kinase 19 (CDK19) has been identified as a promising target due to its high expression in prostate cancer (PCa) cells. This study focuses on optimizing the structure of CDK19-targeted imaging tracers. The linker of the lead compound was optimized based on previous structure–activity relationships and cyclization strategy. Incorporating the spirocyclic structure optimized the binding conformation and increased the binding effect of the ligands, which was also reflected in its increased IC50 value. Mice imaging showed clearer tumor lesions and acceptable tissue safety. In addition, 68Ga-IRM-8c identified three distinct lesions in two advanced CRPC patients, located in the pelvis, sacrum, and prostate. The SUVmax values of these lesions were 3.31, 2.93, and 2.73, respectively, with tumor-to-nontumor (T/NT) ratios of 2.30, 2.59, and 2.42. In conclusion, 68Ga-IRM-8c not only effectively detected lesions in PCa patients, but also preliminarily demonstrated tissue safety, further highlighting the potential of CDK19 in PCa diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Advanced Medical Materials and Devices, Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Tianjin Institutes of Health Science, Institute of Radiation Medicine, Chinese…
- Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tian…
- Department of Nuclear Medicine, Tianjin Cancer Hospital Airport Hospital, National Clinical Research Center for Cancer, Tianjin 300308, China.
- Department of Genitourinary Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research…
ORCID-Profile: Jiang Yu, Yiliang Li
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences
- Tianjin Medical University
- Tianjin Binhai New Area Health Commission General support projects
- Tianjin Science and Technology Commission Enterprise Science and Technology Commissioner Project
- Tianjin Key Medical Discipline Construction Project
Zitieren
APA
Yu, J., Yang, Z., Xu, F., Li, P., Li, Y., Wang, Z., Liu, J., Hou, W., Fu, J., Zhang, Z., Gou, W., Li, Y., & Dai, D. (2025). Optimized CDK19 PET Tracers: Spirocyclic-Driven Design and Prostate Cancer Imaging. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01389
Vancouver
Yu J, Yang Z, Xu F, Li P, Li Y, Wang Z, et al. Optimized CDK19 PET Tracers: Spirocyclic-Driven Design and Prostate Cancer Imaging. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01389
BibTeX
@article{Yu2025,
author = {Yu, Jiang and Yang, Zhao and Xu, Feifei and Li, Panfeng and Li, Yanli and Wang, Ziyang and Liu, Jianjing and Hou, Wenbin and Fu, Jie and Zhang, Zhenting and Gou, Wenfeng and Li, Yiliang and Dai, Dong},
title = {Optimized CDK19 PET Tracers: Spirocyclic-Driven Design and Prostate Cancer Imaging},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.5c01389}
}
EUVIMED